A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Completed · Phase 3 · Has a placebo group

Conditions studied: Familial Chylomicronemia Syndrome

In brief

The purpose of the study was to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Key facts

Study ID
NCT04568434
Run by
Ionis Pharmaceuticals, Inc.
People needed
66
Starts
2020-11-18
Expected to finish
2023-10-17
Last updated by the study team
2025-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.